SkyOak Wealth LLC Purchases Shares of 15,000 Neumora Therapeutics, Inc. (NASDAQ:NMRA)

SkyOak Wealth LLC acquired a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 15,000 shares of the company’s stock, valued at approximately $147,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Amalgamated Bank bought a new position in Neumora Therapeutics during the 4th quarter worth approximately $29,000. Principal Financial Group Inc. bought a new position in shares of Neumora Therapeutics in the second quarter worth approximately $166,000. SG Americas Securities LLC purchased a new position in shares of Neumora Therapeutics in the second quarter worth $566,000. Nan Fung Group Holdings Ltd bought a new stake in Neumora Therapeutics during the 1st quarter valued at $871,000. Finally, Rhumbline Advisers boosted its position in Neumora Therapeutics by 488.3% during the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after buying an additional 85,706 shares during the period. Institutional investors own 47.65% of the company’s stock.

Insider Transactions at Neumora Therapeutics

In related news, CFO Joshua Pinto sold 31,642 shares of Neumora Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $11.78, for a total transaction of $372,742.76. Following the completion of the transaction, the chief financial officer now directly owns 154,658 shares of the company’s stock, valued at approximately $1,821,871.24. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 26.40% of the company’s stock.

Neumora Therapeutics Trading Up 4.1 %

NMRA stock opened at $12.21 on Thursday. Neumora Therapeutics, Inc. has a fifty-two week low of $8.33 and a fifty-two week high of $21.00. The business’s 50 day moving average price is $11.68 and its two-hundred day moving average price is $11.47.

Neumora Therapeutics (NASDAQ:NMRA) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting the consensus estimate of ($0.37). Equities research analysts anticipate that Neumora Therapeutics, Inc. will post -1.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $29.00 price objective on shares of Neumora Therapeutics in a research report on Wednesday, September 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday, September 12th. Finally, Mizuho began coverage on Neumora Therapeutics in a report on Monday, July 8th. They issued an “outperform” rating and a $20.00 price objective for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.11.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.